Recent News

• 09.09.2025 - H.C. Wainwright 27th Annual Global Investment Conference
• 09.09.2025 - H.C. Wainwright 27th Annual Global Investment Conference
• 09.08.2025 - Keros Therapeutics Presents Additional Clinical Data from its KER-065 Program at the American Society of Bone and Mineral Research 2025 Annual Meeting
• 09.08.2025 - Keros Therapeutics Presents Additional Clinical Data from its KER-065 Program at the American Society of Bone and Mineral Research 2025 Annual Meeting
• 09.04.2025 - 2025 Wells Fargo Healthcare Conference
• 09.04.2025 - 2025 Wells Fargo Healthcare Conference
• 08.28.2025 - Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences
• 08.28.2025 - Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences
• 08.20.2025 - Keros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy
• 08.20.2025 - Keros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy

Recent Filings

• 09.05.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.28.2025 - EX-99.1 EX-99.1
• 08.28.2025 - 8-K Current report
• 08.21.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 08.20.2025 - 8-K Current report
• 08.20.2025 - EX-99.1 EX-99.1
• 08.15.2025 - 3 Initial statement of beneficial ownership of securities
• 08.15.2025 - 3 Initial statement of beneficial ownership of securities